DSpace About DSpace Software
 

Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1774

Title: A randomised clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago Hospital, Uganda
Authors: Kaye, Daniel Kabonge
Nshemerirwe, Ruth
Mutyaba, Twaha Serunjogi
Ndeezi, Grace
Keywords: Pregnancy
Uncomplicated malaria
Artemether-Lumefantrine
Chlorproguanil-Dapsone
Malaria
Africa
Public health
Uganda
Antimalarial therapy
Issue Date: 2008
Publisher: Open Learning on Enteric Pathogens
Citation: Kaye, D., Nshemerirwe, R., Mutyaba, T.S., Ndeezi, G. (2008). A randomised clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago Hospital, Uganda. Journal of Infection in Developing Countries, 2(2)
Abstract: Background: Malaria infection during pregnancy is a major public health problem. Due to increasing resistance to Chloroquine and Sulphadoxine/Pyrimethamine, the Ugandan national policy on malaria treatment was changed in 2005 to Artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. The policy recommends assessment of safety and efficacy of alternative drugs for treatment of uncomplicated malaria. We compared the efficacy and safety of Artemether-Lumefantrine (Coartem®) and Chlorproguanil-Dapsone (Lapdap®) in the management of uncomplicated malaria in pregnancy. Results: Of the 100 women who completed the study, there was no statistically significant difference in clinical and parasitological response by Day 4. The mean fever clearance time 3.0 days with Lapdap® versus 2.5 days with Coartem® was comparable. Likewise, mean parasite clearance time of 2.4 and 2.2 days for Lapdap® and Coartem® respectively was comparable. The adverse effects were comparable between the two groups. Conclusion: Artemether-Lumefantrine and Chlorproguanil-Dapsone have high and comparable cure rates and similar safety profiles when used for treatment of uncomplicated malaria in pregnancy. Methodology: We enrolled 110 pregnant women in the second and third trimester of pregnancy who presented to Mulago hospital, Uganda, with uncomplicated malaria. The study design was an open-label randomized clinical trial. Participants were randomized to receive either Artemether-Lumefantrine (Coartem® 20mg/120mg) orally or Chlorproguanil-Dapsone (Lapdap®) orally for 3 consecutive days. Primary endpoints were clinical and parasitological response assessed on days 0, 1, 2, 4, 7, 14 and 28. Adverse effects, clinical response (treatment failure) and parasitological response were compared. Analysis was by intention to treat.
URI: http://hdl.handle.net/123456789/1774
ISSN: 1972-2680
Appears in Collections:Research Articles (Health-Sciences)

Files in This Item:

File Description SizeFormat
kaye-chs-res.pdf63KbAdobe PDFView/Open

All items in DSpace are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2005 MIT and Hewlett-Packard - Feedback